MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Industry: By Sector
Medical Device Sector
Trauma, Blood, Wound Healing & Emergency Sector
*Driving Forces: Medical Devices & Technology (Trends)
2014: The top three players in Point of Care diagnostics are Alere, Danaher (NYSE: DHR), and Roche
Danaher Corporation (NYSE:DHR)
Finance & Acquisitions: Danaher
Cepheid (NASDAQ: CPHD)
Organization & Developments: Cepheid
Parents
Cepheid (NASDAQ: CPHD)
Children
2010: WHO says Cepheid rapid test will transform TB care (2010)
2014: Cepheid (NASDAQ: CPHD) and Becton, Dickinson and Company (NYSE: BDX) are among the companies also developing point-of-care tests similar to Lucigen’s
2014: Cepheid Partners with AstraZeneca, GSK, Cubist to Develop Rapid Dx for Drug-Resistant Pathogens
2017: U.S. Army_MEDCOM_CEPHEID
2017: VA_65--Brand Name Only Cephied Reagents
2017: VA_66--MRSA - Cepheid
2019: U.S. Army_MEDCOM_For the purchase of reagents for MRSA testing_Justification and Approval
2020: Cepheid wins 1st FDA nod for point-of-care coronavirus test
2022: VA_6515--INTENT TO SOLE SOURCE CEPHEID GENEXPERT REAGENTS_SAM.gov
2024: DLA_Cepheid awarded (SPE2DE-24-D-0013, $49,000,000) multiple award contract for laboratory equipment, accessories and consumables for the Defense Logistics Agency Electronic Catalog, issued against solicitation SPE2DE-22-R0006 and awarded Feb. 24, 2023.
And Identifying Bio-terrorism Agents in the Biothreat/biodefense Market.
Cepheid's easy-to-use systems integrate a number of complicated and time-intensive steps, including sample preparation, DNA amplification and detection, which enable the analysis of complex biological samples in its proprietary test cartridges.
Develops, manufactures, and markets fully-integrated systems and tests for genetic analysis in the clinical, industrial and biothreat/biodefense markets.
Food, Agricultural, and Environmental Testing in the Industrial Market
On-demand molecular diagnostics company
Such as identifying infectious disease and cancer in the clinical market
The Company's systems enable rapid, sophisticated genetic testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures.
Through its strong molecular biology capabilities, the Company is focusing on those applications where rapid molecular testing is particularly important
Jumps
*Key People: Cepheid
Finance & Acquisitions: Cepheid